Neil Pravin Shah, MD, PhD
Professor
Medicine
School of Medicine

Education & Training

Show all (2) Hide

• Diversity, Equity, and Inclusion Champion Training University of California 2019
• M.D. School of Medicine University of California Los Angeles 1996

Websites

Show all (1) Hide

• Clinical Profile at UCSF Medical Center (ucsfhealth.org)

Grants and Projects

Show all (5) Hide

• Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML, NIH, 2015-2019
• Crenolanib and ponatinib for the treatment of FLT3 mutant AML, NIH, 2013-2018
• Mechanisms of resistance to clinically-effective FLT3 kinase inhibitors in AML, NIH, 2012-2017
• Pre-IND study of PMT-254, a pan-FLT3 inhibitor for the treatment of FLT3 driven cancers., NIH, 2015-2016
• Bio-Organic Biomedical Mass Spectrometry Resource, NIH, 1982-2015

Publications (110)

Top publication keywords:
Drug Resistance, NeoplasmImatinib MesylateBenzamidesAntineoplastic AgentsLeukemia, Myeloid, Chronic-PhaseBenzothiazolesThiazolesPiperazinesFusion Proteins, bcr-ablfms-Like Tyrosine Kinase 3PyrrolesDasatinibPyrimidinesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase Inhibitors

• Artificial Intelligence-Assisted Cancer Status Detection in Radiology Reports.
  Cancer research communications 2024 Arya A, Niederhausern A, Bahadur N, Shah NJ, Nichols C, Chatterjee A, Philip J
• Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2024 Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore JO, Oehler V, Pratz K, Pusic I, Rose MG…
• Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
  Leukemia 2024 Jabbour E, Apperley J, Cortes J, Rea D, Deininger M, Abruzzese E, Chuah C, DeAngelo DJ, Hochhaus A, Lipton JH, Mauro M, Nicolini F, Pinilla-Ibarz J, Rosti G, Rousselot P, Shah NP, Talpaz M, Vorog A, …
• Complex Genomic Rearrangements Involving ETV6::ABL1 Gene Fusion in an Individual with Myeloid Neoplasm.
  Genes 2023 Qi Z, Smith C, Shah NP, Yu J
• Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
  British journal of haematology 2023 Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson SM, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH

Show all (105 more) Hide

• Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.
  Journal of the National Cancer Institute 2022 Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, Silver RT, Thompson JE, Flynn KE
• Inflammatory Bowel Disease in Patients with Congenital Chloride Diarrhoea.
  Journal of Crohn's & colitis 2021 Norsa L, Berni Canani R, Duclaux-Loras R, Bequet E, Köglmeier J, Russell RK, Uhlig HH, Travis S, Hollis J, Koletzko S, Grimaldi G, Castaldo G, Rodrigues A, Deflandre J, Dembinski L, Shah N, Heinz-…
• The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment.
  Haematologica 2021 Tran TH, Nguyen JV, Stecula A, Akutagawa J, Moorman AV, Braun BS, Sali A, Mullighan CG, Shah NP, Dai Y, Devidas M, Roberts KG, Smith CC, Loh ML
• Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Smith CC, Viny AD, Massi E, Kandoth C, Socci ND, Rapaport F, Najm M, Medina-Martinez JS, Papaemmanuil E, Tarver TC, Hsu HH, Le MH, West B, Bollag G, Taylor BS, Levine RL, Shah NP
• Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease.
  Nature communications 2020 Serra EG, Schwerd T, Moutsianas L, Cavounidis A, Fachal L, Pandey S, Kammermeier J, Croft NM, Posovszky C, Rodrigues A, Russell RK, Barakat F, Auth MKH, Heuschkel R, Zilbauer M, Fyderek K, Braegger C,…
• Alterations in T and B Cell Receptor Repertoires Patterns in Patients With IL10 Signaling Defects and History of Infantile-Onset IBD.
  Frontiers in immunology 2020 Werner L, Lee YN, Rechavi E, Lev A, Yerushalmi B, Ling G, Shah N, Uhlig HH, Weiss B, Somech R, Snapper SB, Shouval DS
• Long-term Outcomes of Paediatric Patients Admitted With Acute Severe Colitis- A Multicentre Study From the Paediatric IBD Porto Group of ESPGHAN.
  Journal of Crohn's & colitis 2019 Krauthammer A, Tzivinikos C, Assa A, Miele E, Strisciuglio C, Urlep D, Serban ED, Singh A, Winter HS, Russell RK, Hojsak I, Malham M, Navas-López VM, Croft NM, Lee HM, Ledder O, Shamasneh I, Hussey S,…
• Janus kinase inhibition for autoinflammation in patients with DNASE2 deficiency.
  The Journal of allergy and clinical immunology 2019 Hong Y, Capitani M, Murphy C, Pandey S, Cavounidis A, Takeshita H, Nanthapisal S, Yasuda T, Bader-Meunier B, McCreary D, Omoyinmi E, Rao A, Booth C, Gilmour K, Sebire N, Shah N, Klein N, Bullock AN, …
• Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.
  Leukemia & lymphoma 2019 Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson S, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Pane F, Nicolini FE, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH
• Diagnosis and management of children with Blue Rubber Bleb Nevus Syndrome: A multi-center case series.
  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2019 Isoldi S, Belsha D, Yeop I, Uc A, Zevit N, Mamula P, Loizides AM, Tabbers M, Cameron D, Day AS, Abu-El-Haija M, Chongsrisawat V, Briars G, Lindley KJ, Koeglmeier J, Shah N, Harper J, Syed SB, Thomson …
• ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.
  Cancer research 2019 Apsel Winger B, Cortopassi WA, Garrido Ruiz D, Ding L, Jang K, Leyte-Vidal A, Zhang N, Esteve-Puig R, Jacobson MP, Shah NP
• Sub-10-minute High-quality Diagnostic Colonoscopy With Terminal Ileum Intubation in Children Is Feasible and Safe.
  Journal of pediatric gastroenterology and nutrition 2019 Thomson M, Eltumi M, Singh C, Eyles M, Shah N, Vadamalayan B, Chong S, Thapar N, D'Ambrosio A, Isoldi S
• Corrigendum: Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
  Journal of Crohn's & colitis 2018 Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, Shah N, Shaoul R, Wolters VM, Rodrigues A, Uhlig HH, Posovszky C, Kolho KL, Jakobsen C, Cohen S, Shouval DS, de Meij T, Martin-de-Carpi …
• Detecting inflammation in inflammatory bowel disease - how does ultrasound compare to magnetic resonance enterography using standardised scoring systems?
  Pediatric radiology 2018 Barber JL, Zambrano-Perez A, Olsen ØE, Kiparissi F, Baycheva M, Knaflez D, Shah N, Watson TA
• Front-Line Treatment Options for Chronic-Phase Chronic Myeloid Leukemia.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Shah NP
• Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
  Journal of Crohn's & colitis 2017 Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, Shah N, Shaoul R, Wolters VM, Rodrigues A, Uhlig HH, Posovszky C, Kolho KL, Jakobsen C, Cohen S, Shouval DS, de Meij T, Martin-de-Carpi …
• Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
  Annals of hematology 2017 Saglio G, le Coutre P, Cortes J, Mayer J, Rowlings P, Mahon FX, Kroog G, Gooden K, Subar M, Shah NP
• Iodine Status and Growth in Cow's Milk Allergy.
  Journal of pediatric gastroenterology and nutrition 2017 Seward H, Meyer R, Shah N
• Paediatric magnetic resonance enteroclysis under general anaesthesia - initial experience.
  Pediatric radiology 2017 Sadigh S, Chopra M, Sury MR, Shah N, Olsen ØE, Watson TA
• Establishing the prevalence of low vitamin D in non-immunoglobulin-E mediated gastrointestinal food allergic children in a tertiary centre.
  The World Allergy Organization journal 2017 Foong RX, Meyer R, Dziubak R, Lozinsky AC, Godwin H, Reeve K, Hussain ST, Nourzaie R, Shah N
• NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.
  Journal of the National Comprehensive Cancer Network : JNCCN 2016 Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G, Jagasia M, Kantarjian HM, Kropf P, Metheny L, Moore JO, Ontiveros E, Purev E, Quiery A,…
• The impact of the elimination diet on growth and nutrient intake in children with food protein induced gastrointestinal allergies.
  Clinical and translational allergy 2016 Meyer R, De Koker C, Dziubak R, Godwin H, Dominguez-Ortega G, Chebar Lozinsky A, Skrapac AK, Gholmie Y, Reeve K, Shah N
• Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
  American journal of hematology 2016 Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G
• Phenotypic and Genotypic Characterisation of Inflammatory Bowel Disease Presenting Before the Age of 2 years.
  Journal of Crohn's & colitis 2016 Kammermeier J, Dziubak R, Pescarin M, Drury S, Godwin H, Reeve K, Chadokufa S, Huggett B, Sider S, James C, Acton N, Cernat E, Gasparetto M, Noble-Jamieson G, Kiparissi F, Elawad M, Beales PL, Sebire …
• Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A
• Histopathological features of gastrointestinal mucosal biopsies in children with juvenile idiopathic arthritis.
  Pediatric research 2016 Pichler J, Ong C, Shah N, Sebire N, Kiparrissi F, Borrelli O, Pilkington C, Elawad M
• Detecting inflammation in the unprepared pediatric colon - how reliable is magnetic resonance enterography?
  Pediatric radiology 2016 Barber JL, Lozinsky AC, Kiparissi F, Shah N, Watson TA
• Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis.
  European journal of gastroenterology & hepatology 2015 Volonaki E, Mutalib M, Kiparissi F, Shah N, Lindley KJ, Elawad M
• Systematic review of the impact of feed protein type and degree of hydrolysis on gastric emptying in children.
  BMC gastroenterology 2015 Meyer R, Foong RX, Thapar N, Kritas S, Shah N
• Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
  American journal of hematology 2015 Shah NP, Wallis N, Farber HW, Mauro MJ, Wolf RA, Mattei D, Guha M, Rea D, Peacock A
• PPARγ: Welcoming the New Kid on the CML Stem Cell Block.
  Cancer cell 2015 Apsel Winger B, Shah NP
• Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.
  Scientific reports 2015 Kesarwani M, Huber E, Kincaid Z, Evelyn CR, Biesiada J, Rance M, Thapa MB, Shah NP, Meller J, Zheng Y, Azam M
• Time to symptom improvement using elimination diets in non-IgE-mediated gastrointestinal food allergies.
  Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2015 Lozinsky AC, Meyer R, De Koker C, Dziubak R, Godwin H, Reeve K, Dominguez Ortega G, Shah N
• Cow's Milk Protein Allergy from Diagnosis to Management: A Very Different Journey for General Practitioners and Parents.
  Children (Basel, Switzerland) 2015 Lozinsky AC, Meyer R, Anagnostou K, Dziubak R, Reeve K, Godwin H, Fox AT, Shah N
• Histological findings in infants with Gastrointestinal food allergy are associated with specific gastrointestinal symptoms; retrospective review from a tertiary centre.
  BMC clinical pathology 2015 Shah N, Foong RM, Borrelli O, Volonaki E, Dziubak R, Meyer R, Elawad M, Sebire NJ
• Nutritional status in children with Shwachman-diamond syndrome.
  Pancreas 2015 Pichler J, Meyer R, Köglmeier J, Ancliff P, Shah N
• Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.
  Cancer discovery 2015 Smith CC, Zhang C, Lin KC, Lasater EA, Zhang Y, Massi E, Damon LE, Pendleton M, Bashir A, Sebra R, Perl A, Kasarskis A, Shellooe R, Tsang G, Carias H, Powell B, Burton EA, Matusow B, Zhang J, Spevak W…
• A practical approach to vitamin and mineral supplementation in food allergic children.
  Clinical and translational allergy 2015 Meyer R, De Koker C, Dziubak R, Skrapac AK, Godwin H, Reeve K, Chebar-Lozinsky A, Shah N
• Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy.
  eLife 2014 Warkentin AA, Lopez MS, Lasater EA, Lin K, He BL, Leung AY, Smith CC, Shah NP, Shokat KM
• Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.
  Cell reports 2014 Chatterjee A, Ghosh J, Ramdas B, Mali RS, Martin H, Kobayashi M, Vemula S, Canela VH, Waskow ER, Visconte V, Tiu RV, Smith CC, Shah N, Bunting KD, Boswell HS, Liu Y, Chan RJ, Kapur R
• Dietary elimination of children with food protein induced gastrointestinal allergy - micronutrient adequacy with and without a hypoallergenic formula?
  Clinical and translational allergy 2014 Meyer R, De Koker C, Dziubak R, Godwin H, Dominguez-Ortega G, Shah N
• Feeding difficulties in children with food protein-induced gastrointestinal allergies.
  Journal of gastroenterology and hepatology 2014 Meyer R, Rommel N, Van Oudenhove L, Fleming C, Dziubak R, Shah N
• The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children.
  Journal of Crohn's & colitis 2014 Mutalib M, Borrelli O, Blackstock S, Kiparissi F, Elawad M, Shah N, Lindley K
• Targeted gene panel sequencing in children with very early onset inflammatory bowel disease--evaluation and prospective analysis.
  Journal of medical genetics 2014 Kammermeier J, Drury S, James CT, Dziubak R, Ocaka L, Elawad M, Beales P, Lench N, Uhlig HH, Bacchelli C, Shah N
• Sensitive and selective plasmon ruler nanosensors for monitoring the apoptotic drug response in leukemia.
  ACS nano 2014 Tajon CA, Seo D, Asmussen J, Shah N, Jun YW, Craik CS
• The diagnostic approach to monogenic very early onset inflammatory bowel disease.
  Gastroenterology 2014 Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A, Ouahed J, Wilson DC, Travis SP, Turner D, Klein C, Snapper SB, Muise AM, COLORS in IBD Study Group and NEOPICS
• Crenolanib is a selective type I pan-FLT3 inhibitor.
  Proceedings of the National Academy of Sciences of the United States of America 2014 Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP
• Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.
  Blood 2014 Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G
• MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction.
  Cancer discovery 2013 Asmussen J, Lasater EA, Tajon C, Oses-Prieto J, Jun YW, Taylor BS, Burlingame A, Craik CS, Shah NP
• Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.
  Leukemia research 2013 Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP
• What does a deep molecular response signify?
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Politi J, Shah NP
• Phenotypic characterization of very early-onset IBD due to mutations in the IL10, IL10 receptor alpha or beta gene: a survey of the Genius Working Group.
  Inflammatory bowel diseases 2013 Pigneur B, Escher J, Elawad M, Lima R, Buderus S, Kierkus J, Guariso G, Canioni D, Lambot K, Talbotec C, Shah N, Begue B, Rieux-Laucat F, Goulet O, Cerf-Bensussan N, Neven B, Ruemmele FM
• Duodenal haematoma following endoscopy as a marker of coagulopathy.
  Pediatric radiology 2013 Hameed S, McHugh K, Shah N, Arthurs OJ
• Chronic Myelogenous Leukemia, Version 1.2014.
  Journal of the National Comprehensive Cancer Network : JNCCN 2013 O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Pinilla-Ibarz J, Reddy VV, Shah NP, …
• The role of pre- and probiotics in infant nutrition.
  The journal of family health care 2013 Meyer R, Shah N
• Manifestations of food protein induced gastrointestinal allergies presenting to a single tertiary paediatric gastroenterology unit.
  The World Allergy Organization journal 2013 Meyer R, Fleming C, Dominguez-Ortega G, Lindley K, Michaelis L, Thapar N, Elawad M, Chakravarti V, Fox AT, Shah N
• The role of endoscopy and biopsy in the management of severe gastrointestinal disease in cystic fibrosis patients.
  Pediatric pulmonology 2013 Shah N, Tan HL, Sebire N, Suri R, Leuven K
• Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
  Blood 2013 Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP
• The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2013 Smith CC, Shah NP
• Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation.
  The Journal of allergy and clinical immunology 2012 Engelhardt KR, Shah N, Faizura-Yeop I, Kocacik Uygun DF, Frede N, Muise AM, Shteyer E, Filiz S, Chee R, Elawad M, Hartmann B, Arkwright PD, Dvorak C, Klein C, Puck JM, Grimbacher B, Glocker EO
• Front-line TKI therapy for chronic-phase CML: the luxury of choice.
  Oncology (Williston Park, N.Y.) 2012 Shah NP
• Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease.
  Current allergy and asthma reports 2012 Shah N, Kammermeier J, Elawad M, Glocker EO
• Gastrointestinal endoscopy and mucosal biopsy in the first year of life: indications and outcome.
  Journal of pediatric gastroenterology and nutrition 2012 Volonaki E, Sebire NJ, Borrelli O, Lindley KJ, Elawad M, Thapar N, Shah N
• Cow's milk challenge increases weakly acidic reflux in children with cow's milk allergy and gastroesophageal reflux disease.
  The Journal of pediatrics 2012 Borrelli O, Mancini V, Thapar N, Giorgio V, Elawad M, Hill S, Shah N, Lindley KJ
• Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
  Nature 2012 Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP
• Advancing the STATus of MPN pathogenesis.
  Blood 2012 Shah NP, Shannon K
• Practical dietary management of protein energy malnutrition in young children with cow's milk protein allergy.
  Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2012 Meyer R, Venter C, Fox AT, Shah N
• Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2012 Smith CC, Shah NP
• IL-10 and IL-10 receptor defects in humans.
  Annals of the New York Academy of Sciences 2011 Glocker EO, Kotlarz D, Klein C, Shah N, Grimbacher B
• Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.
  Clinical advances in hematology & oncology : H&O 2011 Shah NP
• Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Smith CC, Shah NP
• BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.
  The Journal of experimental medicine 2011 Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, Shah NP, Melnick AM, Müschen M
• Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease.
  Hematology. American Society of Hematology. Education Program 2011 Smith CC, Shah NP
• Infant colitis--it's in the genes.
  Lancet (London, England) 2010 Glocker EO, Frede N, Perro M, Sebire N, Elawad M, Shah N, Grimbacher B
• Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
  American journal of hematology 2010 Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G
• Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
  Haematologica 2010 Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A
• Fine-tuning targeted therapy of CML.
  Blood 2009 Shah NP
• Inflammatory bowel disease and mutations affecting the interleukin-10 receptor.
  The New England journal of medicine 2009 Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, …
• Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib.
  Leukemia research 2009 Paquette RL, Nicoll J, Chalukya M, Gondek L, Jasek M, Sawyers CL, Shah NP, Maciejewski J
• Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
  Cancer 2009 Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP
• Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
  Cancer research 2009 Seeliger MA, Ranjitkar P, Kasap C, Shan Y, Shaw DE, Shah NP, Kuriyan J, Maly DJ
• Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
  Cancer cell 2008 Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL
• Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, …
• Successful treatment of extensive infantile hemangiomatosis of the small bowel in a 3-month-old with thalidomide and somatostatin analog.
  Journal of pediatric gastroenterology and nutrition 2008 Jarvi K, Roebuck DJ, Sebire NJ, Lindley K, Shah N, Salomon J, Curry JI
• Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
  Leukemia 2008 Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, …
• Advanced CML: therapeutic options for patients in accelerated and blast phases.
  Journal of the National Comprehensive Cancer Network : JNCCN 2008 Shah NP
• Treatment of intractable ulcerating enterocolitis of infancy by allogeneic bone marrow transplantation.
  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2008 Thapar N, Lindley KJ, Kiparissi F, Elawad MA, Ashworth M, Veys P, Gaspar HB, Hill SM, Milla PJ, Shah N
• Progressive thoughts about progressive disease.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Shah NP
• Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
  The Journal of clinical investigation 2007 Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL
• Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
  Blood 2007 Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J, Hughes T, Countouriotis A, Shah…
• ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.
  Blood 2007 Shankar DB, Li J, Tapang P, Owen McCall J, Pease LJ, Dai Y, Wei RQ, Albert DH, Bouska JJ, Osterling DJ, Guo J, Marcotte PA, Johnson EF, Soni N, Hartandi K, Michaelides MR, Davidsen SK, Priceman SJ, …
• Dasatinib.
  Drugs of today (Barcelona, Spain : 1998) 2007 Shah NP
• Medical management of CML.
  Hematology. American Society of Hematology. Education Program 2007 Shah NP
• Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
  Blood 2006 Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M
• Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
  Blood 2006 Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, …
• Gene expression changes associated with progression and response in chronic myeloid leukemia.
  Proceedings of the National Academy of Sciences of the United States of America 2006 Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS
• Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
  Cancer research 2006 Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J
• Dynamics of chronic myeloid leukaemia.
  Nature 2005 Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA
• Long-term outcome of intractable ulcerating enterocolitis of infancy.
  Journal of pediatric gastroenterology and nutrition 2005 Thapar N, Shah N, Ramsay AD, Lindley KJ, Milla PJ
• Loss of response to imatinib: mechanisms and management.
  Hematology. American Society of Hematology. Education Program 2005 Shah NP
• Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
  Blood 2004 Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, Bhatia R
• Overriding imatinib resistance with a novel ABL kinase inhibitor.
  Science (New York, N.Y.) 2004 Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL
• Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.
  Oncogene 2003 Shah NP, Sawyers CL
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
  Cancer cell 2002 Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL
• Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
  Proceedings of the National Academy of Sciences of the United States of America 2002 Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA